{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:29:51Z","timestamp":1791480591250,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ctrv.2021.102241","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T03:51:59Z","timestamp":1623210719000},"page":"102241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)"],"prefix":"10.1016","volume":"99","author":[{"given":"Daniel L.","family":"Hertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Faithfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen T.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Marie","family":"McGlown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Grech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ctrv.2021.102241_b0005","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","article-title":"Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/0284186X.2014.980912","article-title":"Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry","volume":"54","author":"Beijers","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2021.102241_b0020","doi-asserted-by":"crossref","unstructured":"Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012;14(Suppl 4):iv45-5doi: 10.1093\/neuonc\/nos203.","DOI":"10.1093\/neuonc\/nos203"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102241_b0025","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2021.102241_b0030","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry","volume":"31","author":"Mols","year":"2013","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology\/NSABP B-30","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx140","article-title":"Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review","volume":"110","author":"Rivera","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0045","doi-asserted-by":"crossref","first-page":"E2400","DOI":"10.3390\/jcm9082400","article-title":"Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study","volume":"9","author":"Selvy","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102241_b0050","first-page":"5059","article-title":"Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)","volume":"24","author":"Pachman","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2021.102241_b0055","doi-asserted-by":"crossref","unstructured":"Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64(6):1076-7 doi 64\/6\/1076 [pii].","DOI":"10.1212\/01.WNL.0000154642.45474.28"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol: Off J Europ Soc Med Oncol\/ESMO"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0065","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0070","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1188\/13.CJON.138-144","article-title":"Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management","volume":"17","author":"Tofthagen","year":"2013","journal-title":"Clin J Oncol Nurs"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102241_b0075","first-page":"01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"14","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102241_b0080","doi-asserted-by":"crossref","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306-19. doi: 10.016\/j.annonc.2020.07.003. Epub Jul 30.","DOI":"10.1016\/j.annonc.2020.07.003"},{"issue":"21","key":"10.1016\/j.ctrv.2021.102241_b0085","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102241_b0090","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0095","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102241_b0100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102241_b0105","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102241_b0110","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1996.14.6.1858","article-title":"Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer","volume":"14","author":"Nabholtz","year":"1996","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102241_b0115","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","article-title":"Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study","volume":"21","author":"Omura","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2021.102241_b0125","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 2020;21(12):1620-9. doi: 10.016\/S470-2045(20)30527-1.","DOI":"10.1016\/S1470-2045(20)30527-1"},{"issue":"33","key":"10.1016\/j.ctrv.2021.102241_b0130","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2011.40.6405","article-title":"Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101","volume":"30","author":"Shulman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102241_b0135","doi-asserted-by":"crossref","unstructured":"Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2\u2008\u00d7\u20082 factorial, randomised phase 3 trial. Lancet 2015;385(9980):1863-72. doi: 10.016\/S0140-6736(14)62048-1. Epub 2015 Mar 2.","DOI":"10.1016\/S0140-6736(14)62048-1"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0140","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0145","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.24043","article-title":"Immortal time bias and reverse causality in retrospective analysis: Comment on \u201ceffect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study\u201d","volume":"90","author":"Hsieh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2021.102241_b0150","doi-asserted-by":"crossref","unstructured":"Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. doi: 10.1002\/brb3.1312. Epub 2019 May 7.","DOI":"10.1002\/brb3.1312"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102241_b0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102241_b0160","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/tbj.14123","article-title":"Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer","volume":"26","author":"Pabst","year":"2020","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3988\/jcn.2018.14.1.81","article-title":"A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy","volume":"14","author":"Kim","year":"2018","journal-title":"J Clin Neurol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/jns.12097","article-title":"Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study","volume":"19","author":"Briani","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.ctrv.2021.102241_b0180","doi-asserted-by":"crossref","unstructured":"Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, et al. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II\/III colon cancer. Cancer Chemother Pharmacol 2019;84(6):1269-77. doi: 10.007\/s00280-019-3957-5. Epub 2019 Sep 23.","DOI":"10.1007\/s00280-019-03957-5"},{"key":"10.1016\/j.ctrv.2021.102241_b0185","doi-asserted-by":"crossref","unstructured":"Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110(5):1042-9. doi: 10.02\/cncr.22921.","DOI":"10.1002\/cncr.22921"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102241_b0190","first-page":"13697","article-title":"Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response","volume":"1","author":"Timmins","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2021.102241_b0195","unstructured":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials. Lancet 2019;393(10179):1440-52. doi: 10.016\/S0140-6736(18)33137-4. Epub 2019 Feb 8."},{"issue":"23","key":"10.1016\/j.ctrv.2021.102241_b0200","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102241_b0205","doi-asserted-by":"crossref","unstructured":"Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304(1):10-5. doi: 10.1056\/NEJM198101013040103.","DOI":"10.1056\/NEJM198101013040103"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2021.102241_b0210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2017.35.15_suppl.547","article-title":"Adjustments in relative dose intensity (RDI) for FECD chemotherapy in breast cancer: A population analysis","volume":"35","author":"Veitch","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0215","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","article-title":"Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer","volume":"6","author":"Cespedes Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2021.102241_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2021.102241_b0225","article-title":"Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study","author":"de Morree","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2018.07.021","article-title":"Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology\/Gynecologic Oncology Group study","volume":"151","author":"Olawaiye","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0245","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte)","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0250","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.23933","article-title":"Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study","volume":"90","author":"Mateos","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0255","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12094-018-1915-3","article-title":"Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial","volume":"21","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102241_b0260","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0265","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102241_b0270","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","article-title":"Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide","volume":"316","author":"Williams","year":"1987","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102241_b0275","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102241_b0280","first-page":"4163","article-title":"Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study","volume":"28","author":"Salgado","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2021.102241_b0285","doi-asserted-by":"crossref","unstructured":"Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, S\u00fctterlin M. Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes. Front Oncol 2018;8:535.(doi):10.3389\/fonc.2018.00535. eCollection 2018.","DOI":"10.3389\/fonc.2018.00535"},{"issue":"23","key":"10.1016\/j.ctrv.2021.102241_b0290","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.28940","article-title":"Patient preferences in advanced or recurrent ovarian cancer","volume":"120","author":"Havrilesky","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0295","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.pmn.2018.01.001","article-title":"Estimating the Frequency, Severity, and Clustering of SPADE Symptoms in Chronic Painful Chemotherapy-Induced Peripheral Neuropathy","volume":"19","author":"Knoerl","year":"2018","journal-title":"Pain Manag Nurs"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102241_b0300","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102241_b0305","first-page":"3729","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview","volume":"27","author":"Chan","year":"2019","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102241_b0310","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.pec.2019.08.035","article-title":"Do clinicians convey what they intend? Lay interpretation of verbal risk labels used in decision encounters","volume":"103","author":"Kunneman","year":"2020","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.ctrv.2021.102241_b0315","series-title":"National Cancer Survivorship Initative: Text Analysis of Patients\u2019 Free Text Comments: Final Report","author":"Corner","year":"2012"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0320","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1186\/s12885-018-5093-z","article-title":"Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy","volume":"18","author":"Knoerl","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2021.102241_b0325","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/2193-1801-3-366","article-title":"Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience","volume":"3","author":"Bhatnagar","year":"2014","journal-title":"Springerplus"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102241_b0330","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","volume":"125","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102241_b0335","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/cncr.32175","article-title":"Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice","volume":"125","author":"Nyrop","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0340","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1634\/theoncologist.2018-0418","article-title":"Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy","volume":"24","author":"S\u00e1nchez-Barroso","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102241_b0345","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","article-title":"Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial","volume":"7","author":"Scheithauer","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102241_b0350","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s11136-017-1635-0","article-title":"The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice","volume":"26","author":"Simon","year":"2017","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102241_b0355","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","article-title":"Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer","volume":"9","author":"Speck","year":"2013","journal-title":"J Oncol Pract"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102241_b0360","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-18-0656","article-title":"Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy","volume":"24","author":"Hertz","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102241_b0365","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cam4.621","article-title":"Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens","volume":"5","author":"Ali","year":"2016","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0370","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/annonc\/mdp594","article-title":"Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?","volume":"21","author":"Storey","year":"2010","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2021.102241_b0375","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","article-title":"Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group","volume":"23","author":"Gibson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102241_b0380","doi-asserted-by":"crossref","unstructured":"Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19(8):1450-7. doi: 10.093\/annonc\/mdn166. Epub 2008 Jun 16.","DOI":"10.1093\/annonc\/mdn166"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102241_b0385","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102241_b0390","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2021.102241_b0395","first-page":"2669","article-title":"Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"22","author":"Cho","year":"2014","journal-title":"Support Care Cancer"},{"issue":"26","key":"10.1016\/j.ctrv.2021.102241_b0400","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2021.102241_b0405","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722100089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722100089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:27Z","timestamp":1759656447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722100089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":81,"alternative-id":["S030573722100089X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102241","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102241"}}